Matteo Lambertini, MD, PhD, IRCCS Ospedale Policlinico San Martino, Genova, Italy, discusses how biomarkers and novel therapies have changed the management of patients with advanced breast cancer. Dr Lambertini argues that the current breast cancer classification is outdated and that it should include biomarkers such as PD-L1, PIK3CA, and BRCA. In addition, with improved treatments, the choice of primary and secondary endpoints in clinical trials should also change and prioritize overall survival (OS) and quality of life (QoL). Finally, Dr Lambertini underlines the importance of choosing the correct first-line treatment for breast cancer patients to ensure the best prognosis. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.